| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.21 | 6e-08 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-07 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.26 | 7e-07 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.26 | 1e-06 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.27 | 2e-06 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-06 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.17 | 5e-06 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.24 | 1e-05 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.14 | 2e-05 |